There are 2867 resources available
The non-small cell lung cancer paradigm in translating NGS information to clear actionable insights: Standardised reporting, molecular tumour boards and decision-support systems
Presenter: Oliver Gautschi
Session: ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics
Resources:
Webcast
Emerging treatment options for EGFR exon 20 insertions
Presenter: Sanjay Popat
Session: Janssen-Cilag International NV - Precision approaches in EGFR-mutant NSCLC: Optimising outcomes for patients
Resources:
Webcast
Q&A
Presenter: Paul Hofman
Session: Janssen-Cilag International NV - Precision approaches in EGFR-mutant NSCLC: Optimising outcomes for patients
Resources:
Webcast
Key learnings and closing remarks
Presenter: Maria Rosario Garcia Campelo
Session: Janssen-Cilag International NV - Precision approaches in EGFR-mutant NSCLC: Optimising outcomes for patients
Resources:
Webcast
Efficiency of eHealth and digital innovations in cancer care
Presenter: Andreas Charalambous
Session: eHealth and digital innovations
Resources:
Slides
Webcast
Development and implementation of virtual pre-chemotherapy consultations
Presenter: Catherine Oakley
Session: eHealth and digital innovations
Resources:
Slides
Webcast
CN1 - Patient-reported symptom monitoring improves health-related quality of life in lung cancer patients: The SYMPRO-Lung trial
Presenter: Nicole Billingy
Session: eHealth and digital innovations
Resources:
Abstract
CN2 - A public involvement process to enhance diversity in technology clinical trials
Presenter: Leanna Goodwin
Session: eHealth and digital innovations
Resources:
Abstract
617O - Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical results
Presenter: Chunkang Chang
Session: Proffered Paper session: Haematological malignancies
Resources:
Abstract
Slides
Webcast
729MO - Final results of the first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory to prior anti-PD1/PD-L1 treatment
Presenter: Ignacio Melero
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast